This week in therapeutics




Licensing status

Publication and contact information


Breast cancer


Cell culture and mouse studies suggest proteasome inhibitors could help treat basal-like, triple-negative breast cancer. A small interfering RNA screen in two triple-negative breast cancer cell lines identified multiple components of the proteasome that could be inhibited to decrease cell growth. In basal-like, triple-negative breast cancer cell lines, Velcade bortezomib decreased growth, including growth of tumor-initiating cells, compared with vehicle. In a mouse xenograft model of basal-like, triple-negative breast cancer, intratumoral injection of Velcade decreased growth compared with control injection. Next steps include identifying markers to predict triple-negative breast cancer responsiveness to proteasome inhibition.
Takeda Pharmaceutical Co. Ltd. and Johnson & Johnson market the competitive proteasome inhibitor Velcade to treat multiple myeloma and mantle cell lymphoma.

SciBX 6(35); doi:10.1038/scibx.2013.952
Published online Sept. 12, 2013

Patent application filed; available for licensing

Petrocca, F. et al. Cancer Cell; published online Aug. 12, 2013;
Contact: Judy Lieberman, Harvard Medical School, Boston, Mass.

Contact: Fabio Petrocca, same affiliation as above